Rosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, Salvatore Alfieri, Maria Moksnes Bjaanæs, Filippo Pietrantonio, Loris De Cecco, Arsela Prelaj, Claudia Proto, Johan Franzén, Deirdre McDonnell, José Javier Berenguer Pina, Teresa Beninato, Laura Mazzeo, Patrizia Giannatempo, Elena Verzoni, John Crown, Åslaug Helland, Alexander Eustace
BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in various cancers. ICI treatment is associated with the incidence of immune-related adverse events (irAEs) which can affect any organ. Data on irAEs occurrence in relation to sex- differentiation and their association with gender-specific factors are limited. AIMS: The primary objective of the G-DEFINER study is to compare the irAEs incidence in female and male patients who undergo ICI treatment...
April 21, 2024: Acta Oncologica